Immunomedics (IMMU -1.7%) reports that preclinical studies of its lead antibody drug candidate,...


Immunomedics (IMMU -1.7%) reports that preclinical studies of its lead antibody drug candidate, epratuzumab, show the drug to have a distinct way of reducing the immune response of B cells. B cells are responsible for producing antibodies that attack the patient's own body in autoimmune diseases such as lupus. The study results were presented at the 54th Annual Meeting of the American Society of Hematology.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs